CBL-B (22-37) Light ILGIIDAIQDAVGPPK-acid
CBL-B (22-37) is derived from the CBL-B E3 ubiquitin ligase which targets receptor tyrosine kinases to lysosome degradation.
Catalogue number crb1000942 Molecular Weight 1618.9 Sequence (one letter code) ILGIIDAIQDAVGPPK-acid Sequence (three letter code)
Purity >95% Storage -20°C References
Duan et al (2010) Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGFR-mediated epithelial cell adherens junction dynamics and cell migration. J. Biol. Chem. 286(1) 620 doi: http://www.jbc.org/cgi/doi/10.1074/jbc.M110.188086
Kaosheng et al (2017) CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev. 31 1007 doi: http://genesdev.cshlp.org/content/31/10/1007.full.pdf
Manufactured in: United Kingdom
CBL-B (22-37) is derived from the CBL-B E3 ubiquitin ligase which targets receptor tyrosine kinases to lysosome degradation. CBL-B and its family member CBL are expressed in hematopoietic cells and as E3 ubiquitin ligases they contain a tyrosine kinase domain and an RF domain joined by a linker domain. The function of the RF domain is to transfer ubiquitin from E2 ubiquitin-conjugating enzymes onto the target protein which is often phosphorylated. Consequently the ubiquitinated substrate, the receptor tyrosine kinases, are ultimately targeted to the lysosome for degradation.
EGFR is an example of a receptor tyrosine kinase whose activation is prevented by CBL and CBL-B when they bind and recruit GRb2, the adapter protein to EGFR. Consequently the ubiquitinylation of EGFR occurs and targets it for recognition by the endosomal protein complex and then lysosome degradation.
It has also been found that the CBL family can negatively regulate through ubiquitinylation, PI 3-kinases, Rap G-protein guanine nucleotide exchange factor (GEF), C3G and Rho GTPase GEF Vav which are all non-receptors.
If CBL or CBL-B becomes non-functional it can be associated with malignancies such as acute myeloid leukemia and myelodysplastic syndrome.